Characters | Anti-PLA2R positive (n = 18) | Anti-PLA2R negative (n = 12) | P |
---|---|---|---|
Age (years) | 53.6 ± 14.5 | 47.6 ± 14.8 | 0.282 |
Gender (male/female) | 11/7 | 9/3 | 0.694 |
Clinical features | |||
 Urinary protein (g/24 h) | 4.5 (2.7, 8.9) | 2.3 (1.5, 3.9) | 0.025 |
 Serum albumin (g/l) | 27.5 ± 7.5 | 31.9 ± 7.5 | 0.122 |
 Nephrotic syndrome (n, %) | 12 (66.7%) | 2 (16.7%) | 0.011 |
 eGFR (ml/min/1.73m2) | 83.9 ± 28.9 | 93.1 ± 15.3 | 0.269 |
 Anti-PLA2R antibody level (RU/ml) | 84.0 (41.8, 221.5) | 2.8 (1.0, 6.6) |  < 0.001 |
Histological features | n = 15 | n = 12 |  |
 Stages of membranous injury, I/II/III + IV | 7/7/1/0 | 7/5/0/0 | 0.500 |
 Intensity of glomerular IgG deposit | 3.4 ± 0.4 | 3.0 ± 0.7 | 0.150 |
 Glomerular IgG1/IgG2/IgG3/IgG4 deposit, n | 15/7/6/15 | 12/5/3/12 |  |
 C3 deposit, n (%) | 13 (86.7) | 9 (75) | 0.628 |
 Intensity of PLA2R staining | 2.7 ± 0.7 | 2.5 ± 0.6 | 0.426 |